Dr. Cortes Discusses FLT3 Inhibitors in AML

J‚Äčorge E. Cortes, MD
Published: Thursday, Jun 22, 2017



Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses FLT3 Inhibitors in acute myeloid leukemia (AML).

Cortes says that one of the most common mutations in AML is FLT3-internal tandem duplication (ITD). Until recently, there has not been much progress in developing agents for this population.

FLT3 inhibitors under development are quizartinib, crenolanib, and gilteritinib. There have been some good responses with these inhibitors as single agents, says Cortes, but they tend to be transient.
 


Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses FLT3 Inhibitors in acute myeloid leukemia (AML).

Cortes says that one of the most common mutations in AML is FLT3-internal tandem duplication (ITD). Until recently, there has not been much progress in developing agents for this population.

FLT3 inhibitors under development are quizartinib, crenolanib, and gilteritinib. There have been some good responses with these inhibitors as single agents, says Cortes, but they tend to be transient.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x